NEUP (Neuphoria Therapeutics) Cyclically Adjusted FCF per Share: $-1.93 (As of Mar. 2026)


NEUP Neuphoria Therapeutics Inc NEUP
28 GF Score
Price $3.52
! 1 Warning Sign
View Full Analysis

What is Neuphoria Therapeutics Cyclically Adjusted FCF per Share?

Neuphoria Therapeutics NEUP -1.95% 28 Cyclically Adjusted FCF per Share is $-1.93 as of Mar. 2026. GuruFocus rates NEUP with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Neuphoria Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2026 was $-0.617. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-1.93 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Neuphoria Therapeutics was 7.60% per year. The lowest was -120.30% per year. And the median was 3.00% per year.

As of today (2026-07-08), Neuphoria Therapeutics's current stock price is $3.52. Neuphoria Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-1.93. Neuphoria Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Neuphoria Therapeutics  (NAS:NEUP) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Neuphoria Therapeutics Cyclically Adjusted FCF per Share Related Terms


Neuphoria Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Neuphoria Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuphoria Therapeutics Cyclically Adjusted FCF per Share Chart

Neuphoria Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.13 0.00 0.00 -1.39 -1.48

Neuphoria Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.28 -1.48 -1.67 -1.83 -1.93

NEUP vs PLRZ, SKYE, IGC: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Neuphoria Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neuphoria Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neuphoria Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Neuphoria Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


NEUP
28GF Score
Neuphoria Therapeutics Inc NEUP
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neuphoria Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Neuphoria Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.617/330.2130*330.2130
=-0.617

Current CPI (Mar. 2026) = 330.2130.

Neuphoria Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.094 241.018 -0.129
201609 -0.009 241.428 -0.012
201612 0.071 241.432 0.097
201703 0.010 243.801 0.014
201706 -0.097 244.955 -0.131
201709 -0.006 246.819 -0.008
201712 -0.121 246.524 -0.162
201803 0.000 249.554 0.000
201806 -0.135 251.989 -0.177
201809 -0.011 252.439 -0.014
201812 0.031 251.233 0.041
201903 -0.004 254.202 -0.005
201906 -0.100 256.143 -0.129
201909 -0.003 256.759 -0.004
201912 0.030 256.974 0.039
202003 -0.002 258.115 -0.003
202006 -0.037 257.797 -0.047
202009 -0.003 260.280 -0.004
202012 0.001 260.474 0.001
202103 -0.002 264.877 -0.002
202106 -0.049 271.696 -0.060
202109 -0.004 274.310 -0.005
202112 -0.004 278.802 -0.005
202203 -0.002 287.504 -0.002
202206 0.000 296.311 0.000
202209 -0.002 296.808 -0.002
202212 -0.003 296.797 -0.003
202303 -0.004 301.836 -0.004
202306 0.000 305.109 0.000
202309 -0.036 307.789 -0.039
202312 -4.603 306.746 -4.955
202403 -3.359 312.332 -3.551
202406 -3.754 314.175 -3.946
202409 -3.410 315.301 -3.571
202412 -2.132 315.605 -2.231
202503 6.663 319.799 6.880
202506 -1.886 322.561 -1.931
202509 -1.690 324.800 -1.718
202512 -1.419 324.054 -1.446
202603 -0.617 330.213 -0.617

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-1.93 mean?
Neuphoria Therapeutics (NEUP) has a Cyclically Adjusted FCF per Share of $-1.93 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Neuphoria Therapeutics and its competitors.
Is Neuphoria Therapeutics' Cyclically Adjusted FCF per Share too high?
Neuphoria Therapeutics' current Cyclically Adjusted FCF per Share is $-1.93. Overall, Neuphoria Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Neuphoria Therapeutics' Cyclically Adjusted FCF per Share compare to PLRZ and SKYE?
Neuphoria Therapeutics' Cyclically Adjusted FCF per Share of $-1.93 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Neuphoria Therapeutics and its competitors. Neuphoria Therapeutics's current Cyclically Adjusted FCF per Share is $-1.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuphoria Therapeutics stock overvalued right now?
Neuphoria Therapeutics (NEUP) has a current Cyclically Adjusted FCF per Share of $-1.93. The current Cyclically Adjusted FCF per Share is $-1.93. Neuphoria Therapeutics' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Neuphoria Therapeutics (NEUP), the current Cyclically Adjusted FCF per Share is $-1.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neuphoria Therapeutics Business Description

Address 100 Summit Drive, Burlington, MA, USA, 01803
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
28GF Score

Get the complete analysis for NEUP

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.52
Price